Abstract: A method may include acquiring NMR data and sonic data for a borehole in a subsurface geologic region; inverting the NMR data and the sonic data to determine volume fractions for a number of classes of pore types, where the classes include shape and size-based classes; and characterizing the subsurface geologic region based on the volume fractions for the number of classes.

Abstract: A molecular marker for identifying DNA methylation and thereby detecting the benignity or malignancy of a lung nodule is disclosed. The molecular marker for identifying DNA methylation includes the sequence of, or the completely complementary sequence to, SEQ ID NO:6 or a continuous fragment of at least 55% of the full length of the sequence of, or the completely complementary sequence to, SEQ ID NO:6. Also disclosed are applications of the molecular marker for identifying DNA methylation, including a corresponding detection reagent kit and a corresponding detection method. The disclosed molecular marker combinations for identifying DNA methylation are highly correlated to lung cancer, are highly sensitive and specific when used to detect the benignity or malignancy of a lung nodule, and can increase the detection rate of malignant lung nodules while lowering the false positive rate.

Abstract: The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.

Abstract: The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.

Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Abstract: This disclosure provides isolated antibodies, for example, monoclonal antibodies, that specifically bind to the C-C Motif Chemokine Receptor 8 (CCR8) expressed on the surface of a cell and mediate depletion of the CCR8-expressing cell by anti-body-dependent cellular cytotoxicity (ADCC). The disclosure provides methods for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-CCR8 antibody as monotherapy or in combination with an anti-cancer agent such as an immune checkpoint inhibitor, for example, an anti-PD-1 or anti-PD-L1 antibody.

Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Abstract: The present invention relates to a process of fabricating a multi-layer composite structure by 3D printing, said composite structure comprises at least one cured mortar layer formed by curing of a mortar composition, and at least one polyurethane layer formed by polymerization of a first polyurethane forming composition, wherein said mortar composition and said first polyurethane forming composition are dispensed individually and simultaneously via adjacent printing nozzles. The mortar composition is optionally modified by a second polyurethane forming composition.

Abstract: Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.

Abstract: Operations of the present disclosure may include receiving a group of images taken by a camera over time in an environment. The operations may also include identifying a first position of an object in a target region of the environment in a first image of the group of images and identifying a second position of the object in a second image of the group of images. Additionally, the operations may include determining an estimated trajectory of the object based on the first position of the object and the second position of the object. The operations may further include, based on the estimated trajectory, estimating a ground position in the environment associated with a starting point of the estimated trajectory of the object. Additionally, the operations may include providing the ground position associated with the starting point of the estimated trajectory of the object for display in a graphical user interface.

Abstract: The disclosure provides antibodies that specifically bind human IDO and methods of use thereof. In some aspects, the disclosure is directed to methods of detecting IDO in a biological sample comprising contacting the biological sample with an antibody described herein.

Abstract: Operations of the present disclosure may include receiving a group of images taken by a camera over time in an environment. The operations may also include identifying a first position of an object in a target region of the environment in a first image of the group of images and identifying a second position of the object in a second image of the group of images. Additionally, the operations may include determining an estimated trajectory of the object based on the first position of the object and the second position of the object. The operations may further include, based on the estimated trajectory, estimating a ground position in the environment associated with a starting point of the estimated trajectory of the object. Additionally, the operations may include providing the ground position associated with the starting point of the estimated trajectory of the object for display in a graphical user interface.

Abstract: Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.

Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Abstract: An electronic device includes a waterproof case, including a closed space, and a flow guide assembly, an electronic module and a cover, provided in the closed space. The cover includes a cover top plate and a cover side plate which, together with a case bottom plate and a case side plate, form an accommodation space for accommodating the flow guide assembly and the electronic module. Further, the cover includes a first vent hole and a second vent hole. The flow guide assembly is configured to guide air, entering the accommodation space from the first vent hole, to flow through the electronic module and to be discharged from the second vent hole. The flow guide assembly is further configured to guide air, entering the cavity from the first vent hole, to flow through the electronic module and to be discharged from the second vent hole.

Abstract: The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.

Abstract: An apparatus for use in decoding a bar code symbol may include an image sensor integrated circuit having a plurality of pixels, timing, and control circuitry for controlling an image sensor, gain circuitry for controlling gain, and analog to digital conversion circuitry for conversion of an analog signal to a digital signal. The apparatus may also include a PCB for mounting the image sensor integrated circuit and light source bank. The connection between the image sensor integrated circuit and/or light source bank and the PCB characterized by a plurality of wires connecting a plurality of bond pads and a plurality of contact pads, where the wires, bond pads, and contact pads provide electrical input/output and mechanical connections between the image sensor integrated circuit and the PCB. The apparatus may be operative for processing image signals generated by the image sensor integrated circuit for attempting to decode the bar code symbol.

Abstract: Operations of the present disclosure may include receiving a group of images taken by a camera over time in an environment. The operations may also include identifying a first position of an object in a target region of the environment in a first image of the group of images and identifying a second position of the object in a second image of the group of images. Additionally, the operations may include determining an estimated trajectory of the object based on the first position of the object and the second position of the object. The operations may further include, based on the estimated trajectory, estimating a ground position in the environment associated with a starting point of the estimated trajectory of the object. Additionally, the operations may include providing the ground position associated with the starting point of the estimated trajectory of the object for display in a graphical user interface.

Abstract: Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.

Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.